Haemonetics (HAE) Invested Capital (2010 - 2026)

Haemonetics has reported Invested Capital for 17 years, with the latest figure at $2.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital changed 0.46% year-over-year to $2.0 billion; the trailing twelve-month figure through Mar 2026 stood at $2.0 billion (changed 0.46% YoY), and the FY2026 full-year result was $2.0 billion, changed 0.46% from the prior year.
• Invested Capital for Q1 2026 stood at $2.0 billion, down from $2.1 billion in the prior quarter.
• The five-year high for Invested Capital was $2.1 billion in Q4 2025, with the low at $730.8 million in Q1 2022.
• Average Invested Capital over 5 years is $1.3 billion, with a median of $1.1 billion recorded in 2022.
• Year-over-year, Invested Capital dropped 29.03% in 2022 and jumped 135.73% in 2025.
• Tracing HAE's Invested Capital over 5 years: stood at $1.3 billion in 2022, then slipped by 4.59% to $1.2 billion in 2023, then fell by 25.01% to $906.9 million in 2024, then soared by 135.56% to $2.1 billion in 2025, then retreated by 4.68% to $2.0 billion in 2026.
• The last three Invested Capital figures came in at $2.0 billion (Q1 2026), $2.1 billion (Q4 2025), and $2.1 billion (Q3 2025), per Business Quant data.

Peer Comparison